EDIR: Early Discovery of Ischemia After Replantation Surgery of the Extremities

Sponsor
Oslo University Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05297266
Collaborator
Sensocure AS (Other)
60
1
1
17
3.5

Study Details

Study Description

Brief Summary

Investigators will test if changes in CO2 is detected postoperatively in ischemic tissue in a replanted extremity of a traumatically amputated upper or lower extremity. IscAlert is measuring continuously CO2 in muscular and subcutaneous tissue. IscAlert is inserted distal to the operative field into normal muscle and/or subcutaneous tissue in the replanted extremity. Local tissue CO2 and temperature will be monitored continuously postoperatively for the next 10 days. If a reduced or totally obstructed blood flow appear (thrombosis), an increase in tissue CO2 and a lower local temperature will emerge rapidly as a sign of ischemia. This will be detected by the sensor which will alarm the investigators. This will lead to assessment of the replanted extremity and if restricted blood flow is diagnosed, a reoperation will be performed. Sixty patients will be enrolled to undergo the procedures. The IscAlert will be removed from the patient before the patient is discharged from the hospital or a maximum of 10 days (the event that occurs first). 400 devices is planned to be used in this clinical study.

Condition or Disease Intervention/Treatment Phase
  • Device: IscAlert
N/A

Detailed Description

This is an open, prospective, interventional, single-center clinical investigation designed to examine the feasibility and safety of the IscAlert™ device in patients scheduled for extremity replant surgery. Sixty patients will be enrolled to undergo the procedures using a total of 400 devices depending on the injuries.

IscAlert is 0.8 mm in diameter and in vitro testing, shows stable and accurate measurements of pCO2. More than 200 animal experiments have been done with the sensor. The experiments have shown that the sensor detects ischemia (Increased CO2-measurements) in real time in the following organs and tissues: Brain, heart, liver, kidneys, pancreas, intestines, musculature and subcutaneous tissue. Sensitivity and specificity are close to 100%. The sensors are inserted into tissue by a split needle technique. The split needle is the size of a 3-gauge peripheral venous catheter. In animal studies, no complications have been detected when using the sensor.

The IscAlert catheters are connected to an electronics unit that is fixed to the skin with an adhesive plaster or glue outside the sterile area. The electrical signals are redirected to a PC approved for clinical use which continuously records tissue pressures of CO2.

IscAlert is inserted into normal muscle and/or subcutaneous tissue distal on the replanted limb to be operated at the end of surgery or immediate postoperatively. The insertion is far away from the operating field. The insertion is done under sterile conditions in accordance with standard sterility criteria at the hospital. No pain during insertion will occur because of insertion is performed during anesthesia (general or regional). Also, the insertion can be compared to an intramuscular injection.

Postoperatively, the IscAlert sensor will continuously monitoring tissue CO2 and temperature. If ischemia occur, for examples caused by a thrombus, an increase in tissue CO2 and a lower temperature will evolve. This will be detected by the sensor which will alarm the investigators. This will lead to assessment of the replanted extremity and if restricted blood flow is diagnosed or suspected, a reoperation will be performed.

Sixty patients will be enrolled to undergo the procedures. The IscAlert will be removed from the patient before the patient is discharged from the hospital or a maximum of 10 days (the event that occurs first). Approximately 400 devices in 80 injured extremities is planned to be used in this clinical study.

The primary objective is to compare CO2-levels in the replanted extremity in individuals who has undergone extremity replantation surgery and investigate if CO2-level is different in patient diagnosed with obstructed blood flow vs. patients with sufficient blood flow in the replanted extremity.

Our hypotheses are:
  1. The IscAlert™ device will be able to detect the presence of ischemia in the extremity replant by increased pCO2 levels and decrease in tissue temperature, measured by IscAlert™.

  2. By using the IscAlert™ device monitoring ischemic events, an early treatment for ischemia could lead to higher incidence of replantation survival rates, and less revision surgery caused by replantation thrombosis.

  3. No clinically significant bleeding or infection will occur using IscAlert™ in this clinical study.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Intervention Model Description:
Prospective, interventional. Sixty patients (80 injured extremities) will receive tissue CO2 monitoring in the replanted extremity after traumatic amputation replant surgery.Prospective, interventional. Sixty patients (80 injured extremities) will receive tissue CO2 monitoring in the replanted extremity after traumatic amputation replant surgery.
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Early Discovery of Ischemia After Replantation Surgery of the Extremities (EDIR-study) ; An Open, Prospective, Intervention Study
Anticipated Study Start Date :
Aug 1, 2022
Anticipated Primary Completion Date :
Apr 30, 2023
Anticipated Study Completion Date :
Dec 31, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Patients with replanted extremity monitored by tissue CO2

Patients with traumatic amputation of a limb who are undergoing replantation surgery and are monitored postoperatively with IscAlert biosensor measuring local tissue CO2 and temperature in the replanted extremity

Device: IscAlert
Insertion of a CO2- and temperature sensor in the distal part of the replanted extremity

Outcome Measures

Primary Outcome Measures

  1. Tissue CO2-level [10 days]

    Tissue CO2-level (kPa) during insertion period

Secondary Outcome Measures

  1. Bleeding [10 days]

    Amount of blood from insertion site (ml)

  2. Infection [30 days]

    Infection from insertion site at the discretion of the investigator (yes or no)

  3. Length of stay at hospital [30 days]

    Number of days from end of initial operation to primary hospital discharge + Number of days from transfer from primary hospital to discharge from secondary hospital.

  4. Time to reduced blood flow in replanted extremity [10 days]

    Number of days and hours from primary replant surgery end to obstructed blood flow is diagnosed.

  5. Number of re-operations [30 days]

    Number of reoperations caused by replant necrosis/ischemia in the replanted extremity

Other Outcome Measures

  1. Number of pack-years [30 days]

    Smoking habit; number of pack-years by participants

  2. Preoperative ischemia time [12 hours]

    Preoperative ischemia time of the amputated limb (minutes)

  3. Intravenous fluid [12 hours]

    Intravenous fluid given during surgery (ml)

  4. Vasoactive drugs [10 hours]

    Vasoactive drugs given during surgery (microgram)

  5. Arterial CO2 level [10 days]

    Arterial blood gass analysis of CO2 during hospital stay (kPa)

  6. Arterial PH level [10 days]

    Arterial blood gass analysis of PH during hospital stay (kPa)

  7. Arterial oxygen level [10 days]

    Arterial blood gass analysis of oxygen during hospital stay (kPa)

  8. Arterial lactate level [10 days]

    Arterial blood gass analysis of lactate during hospital stay (kPa)

  9. Arterial HCO3- level [10 days]

    Arterial blood gass analysis of HCO3- during hospital stay (kPa)

  10. End-tidal level of CO2 [10 days]

    End-tidal level of CO2 during hospital stay (kPa)

  11. IscAlert functionality [10 days]

    Number of hours with a well-functioning sensor (giving CO2- and temperature data)

  12. Physical examination of the reimplanted extremity - capillary filling [10 days]

    Time of capillary filling (seconds)

  13. Physical examination of the reimplanted extremity - color [10 days]

    Color of reimplanted extremity (Red or Pale)

  14. Physical examination of the reimplanted extremity - SpO2 [10 days]

    SpO2 of reimplanted extremity (%)

  15. Physical examination of the reimplanted extremity - temperature [10 days]

    Temperature of reimplanted extremity (degrees Celsius)

  16. SpO2 [10 days]

    SpO2 measured at a non-affected (healthy) extremity (%)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 100 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients must be in need of extremity replantation surgery

  • Subject must be ≥ 18 years

  • Able to give written signed informed consent

Exclusion Criteria:
  • None

Contacts and Locations

Locations

Site City State Country Postal Code
1 Oslo University Hospital Oslo Norway 0424

Sponsors and Collaborators

  • Oslo University Hospital
  • Sensocure AS

Investigators

  • Principal Investigator: Magne Røkkum, MD, Ph.D, Oslo University Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Magne Røkkum, Professor, Oslo University Hospital
ClinicalTrials.gov Identifier:
NCT05297266
Other Study ID Numbers:
  • REK SØR-ØST B, ref 340841
First Posted:
Mar 28, 2022
Last Update Posted:
Apr 6, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Magne Røkkum, Professor, Oslo University Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 6, 2022